pembrolizumabRecent, repeatedEvidence- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Carboplatin + Pemetrexed + Pembrolizumab” · registered May 2025
- NCT06282575 · Jazz Pharmaceuticals · Phase 3 · live · background · “Pembrolizumab” · registered Feb 2024
- NCT05732831 · Tango Therapeutics, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jan 2023
- NCT05429697 · SMT bio Co., Ltd. · Phase 3 · live · background · “Pembrolizumab” · registered Jun 2022
- NCT05220722 · TriSalus Life Sciences, Inc. · Phase 2 · background · “Pembrolizumab” · registered Jan 2022
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 55 studies | 55 studies | background 8 |
CapecitabineRecent, repeatedEvidence- NCT07328919 · TransThera Sciences (Nanjing), Inc. · Phase 3 · live · comparator · “Oxaliplatin, fluorouracil, calcium folinate, irinotecan, capecitabine” · registered Dec 2025
- NCT06622057 · InnoPharmax Inc. · Phase 3 · live · background · “Capecitabine” · registered Sep 2024
- NCT06109779 · AstraZeneca · Phase 3 · live · background · “Capecitabine” · registered Oct 2023
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Capecitabine” · registered Aug 2021
- NCT04430738 · Pfizer · Phase 2 · live · background · “capecitabine” · registered Jun 2020
| Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized | 33 studies | 44 studies | background 6 · comparator 1 |
GemcitabineRecent, repeatedEvidence- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
- NCT06282575 · Jazz Pharmaceuticals · Phase 3 · live · background · “Gemcitabine” · registered Feb 2024
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Gemcitabine” · registered Aug 2021
- NCT04924062 · Merck & Co., Inc · Phase 3 · background · “Gemcitabine” · registered Jun 2021
- NCT04683939 · BioNTech SE · Phase 2 · background · “Gemcitabine” · registered Dec 2020
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 22 studies | 22 studies | background 11 · comparator 4 |
fludarabineRecent, repeatedPhase 4 trial recordedEvidence- NCT07641036 · Beijing Biotech · Phase 2 · live · background · “Fludarabine” · registered Jun 2026
- NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Fludarabine” · registered Jun 2022
- NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “fludarabine” · registered Apr 2019
| Beijing Biotech18% of its industry studies | 22 studies | 22 studies | background 3 |
CyclophosphamideRecent, repeatedEvidence- NCT07641036 · Beijing Biotech · Phase 2 · live · background · “Cyclophosphamide” · registered Jun 2026
- NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
- NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “cyclophosphamide” · registered Apr 2019
| Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed | 22 studies | 22 studies | background 3 |
Albumin-Bound PaclitaxelRecent, repeatedEvidence- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
- NCT05253053 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Combination Product: Nab-Paclitaxel” · registered Jan 2022
- NCT04742959 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Nab-Paclitaxel” · registered Feb 2021
- NCT04683939 · BioNTech SE · Phase 2 · background · “Nab-paclitaxel” · registered Dec 2020
| Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008) | 22 studies | 11 study | background 4 |
NivolumabRecent, repeatedEvidence- NCT05220722 · TriSalus Life Sciences, Inc. · Phase 2 · background · “Nivolumab” · registered Jan 2022
- NCT05223816 · Virogin Biotech Canada Ltd · Phase 2 · live · background · “Nivolumab Injection [Opdivo]” · registered Dec 2021
- NCT03684811 · Novo Nordisk A/S · Phase 2 · background · “Nivolumab” · registered Sep 2018
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 22 studies | 11 study | background 3 |
durvalumabRecent, repeatedEvidence- NCT06282575 · Jazz Pharmaceuticals · Phase 3 · live · background · “Durvalumab” · registered Feb 2024
- NCT05712356 · Lisata Therapeutics, Inc. · Phase 2 · background · “Durvalumab” · registered Jan 2023
| AstraZeneca84% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2018) | 22 studies | 11 study | background 2 |
IpilimumabRecent, repeatedEvidence- NCT05921760 · Servier Bio-Innovation LLC · Phase 2 · background · “Ipilimumab” · registered Apr 2023
- NCT05220722 · TriSalus Life Sciences, Inc. · Phase 2 · background · “Ipilimumab” · registered Jan 2022
| Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011) | 22 studies | 00 studies | background 2 |